Prognosis

Identify your high risk patients quickly

Freelite can help identify patients with a high risk of progression and poor prognosis*. Several recent studies have indicated its use as an independent marker of prognosis in Multiple Myeloma patients.

Author N Detail
van Rhee et al1 301
"High baseline SFLC levels were a reflection of higher tumour burden, higher degree of disease aggressiveness and light-chain-only MM with its greater propensity for renal failure."
Kyrtsonis et al2 94
"The 5-year disease-specific survival was 82% and 30% in patients with sFLCR lower than and equal or greater than the median, respectively (P=0.0001). sFLCR was an independent prognostic factor."
Snozek et al3 1027
"The serum FLC ratio at initial diagnosis is an important predictor of prognosis in myeloma."
Kyrtsonis et al4 214
"In conclusion, baseline sFLCR appears to be an easily determined powerful, independent and very promising novel prognostic factor for survival in patients with newly diagnosed MM."
Dispenzieri et al5 273
"An abnormal ratio proved to be an independent predictor of adverse outcome - in the case of SMM - progression to active MM."

 

"Unlike baseline and follow up serum and urine M proteins, high sFLC levels at baseline-reflecting
more aggressive disease- and steeper reductions after therapy identified patients with
inferior survival" - van Rhee et al, Blood 20071.

 

* In the USA diagnostic use of this product is restricted to those stated in the product insert

 

References

  1. Frits van Rhee, Vanessa Bolejack, Klaus Hollmig, Mauricio Pineda-Roman, Elias Anaissie, Joshua Epstein, John D. Shaughnessy Jr, Maurizio Zangari, Guido Tricot, Abid Mohiuddin, Yazan Alsayed, Gail Woods, John Crowley, and Bart Barlogie
    "High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis"
    Blood, 2007; 110(3):827-832

    Reference: MKG381 Quantity:

  2. Marie-Christine Kyrtsonis, Theodoros P. Vassilakopoulos, Nicoletta Kafasi, Sotirios Sachanas, Tatiana Tzenou, Argiroula Papadogiannis, Zacharoula Galanism Christina Kalpadakis, Maria Dimou, Elias Kyriakou, Maria K. Angelopoulou, Maria N. Dimopoulou, Marina P. Siakantaris, Evangelia M. Dimitriadou, Styliani I. Kokoris, Panayiotis Panayiotidis and Gerassimos A. Pangalis
    "Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma"
    British Journal of Haematology 2007; 137:240-243

    Reference: MKG370 Quantity:

  3. CLH Snozek, JA Katzmann, RA Kyle, A Dispenzieri, DR Larson, TM Therneau, LJ Melton III, S Kumar, PR Greipp, RJ Clark and SV Rajkumar
    "Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system"
    Leukemia advance online publication, 3 July 2008; doi:10.1038/leu.2008.171

    Reference: MKG452 Quantity:

  4. Kyrtsonis et al.
    "Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure"
    Blood 2007; 110:1490a

  5. Angela Dispenzieri, Robert A. Kyle, Jerry A. Katzmann, Terry M. Therneau, Dirk Larson, Joanne Benson, Raynell J. Clark, L. Joseph Melton III, Morie A. Gertz, Shaji K. Kumar, Rafael Fonseca, Diane F. Jelinek, S. Vincent Rajkumar
    "Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma"
    Blood 2008 111(2):785-789

    Reference: MKG414 Quantity: